Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.
Tranzo, Tilburg School of Social Sciences and Behavioral Research, Tilburg University, Tilburg, the Netherlands.
JAMA Netw Open. 2022 Oct 3;5(10):e2236519. doi: 10.1001/jamanetworkopen.2022.36519.
It is unknown how often breast implant illness (BII) is the indication for revision in women with silicone breast implants.
To examine how often women with silicone breast implants have their implants explanted or replaced because of BII compared with local postoperative complications.
DESIGN, SETTING, AND PARTICIPANTS: A legacy cohort study on breast implant revision surgery was conducted between April 1, 2015, and December 31, 2020, and a prospective cohort study on breast implantation and revision surgery was conducted between April 1, 2015, and December 31, 2019 (with follow-up until December 31, 2020). Data were obtained from the Dutch Breast Implant Registry. Data analysis was performed from September 2021 to August 2022.
Silicone breast implant.
Breast implant revision with the indication BII or local postoperative complications.
All 12 882 cosmetic breast implants (6667 women; mean [SD] age, 50.6 [12.7] years) and 2945 reconstructive breast implants (2139 women, mean [SD] age, 57.9 [11.3] years) in the legacy cohort and all 47 564 cosmetic breast implants (24 120 women, mean [SD] age, 32.3 [9.7] years) and 5928 reconstructive breast implants (4688 women, mean [SD] age, 50.9 [11.5] years) in the prospective cohort were included for analysis. In the prospective cohort, 739 cosmetic breast implants (1.6%) were revised after a median (IQR) time to reoperation of 1.8 (0.9-3.1) years, and 697 reconstructive breast implants (11.8%) were revised after a median (IQR) time to reoperation of 1.1 (0.5-1.9) years. BII was registered as the reason for revision in 35 cosmetic revisions (4.7%) and 5 reconstructive revisions (0.7%) in the prospective cohort, corresponding to 0.1% of the inserted implants. In the legacy cohort, 536 cosmetic revisions (4.2%) and 80 reconstructive breast implant revisions (2.7%) were performed because of BII.
In this cohort study of women with silicone breast implants, BII was an uncommon indication for revision compared with local complications, both in the short and long term. In contrast to the increasing public interest in BII, these results showed that local complications are a far more common reason for breast implant revision.
目前尚不清楚患有硅树脂乳房植入物的女性因乳房植入物疾病(BII)而行乳房植入物修复的频率。
研究与局部术后并发症相比,患有硅树脂乳房植入物的女性因 BII 而行乳房植入物取出或更换的频率。
设计、设置和参与者:一项关于乳房植入物修复手术的回顾性队列研究于 2015 年 4 月 1 日至 2020 年 12 月 31 日进行,一项关于乳房植入和修复手术的前瞻性队列研究于 2015 年 4 月 1 日至 2019 年 12 月 31 日进行(随访至 2020 年 12 月 31 日)。数据来自荷兰乳房植入物登记处。数据分析于 2021 年 9 月至 2022 年 8 月进行。
硅树脂乳房植入物。
乳房植入物修复的指征为 BII 或局部术后并发症。
在回顾性队列中,所有 12882 例美容乳房植入物(6667 名女性;平均[SD]年龄,50.6[12.7]岁)和 2945 例重建乳房植入物(2139 名女性,平均[SD]年龄,57.9[11.3]岁),以及前瞻性队列中的所有 47564 例美容乳房植入物(24120 名女性,平均[SD]年龄,32.3[9.7]岁)和 5928 例重建乳房植入物(4688 名女性,平均[SD]年龄,50.9[11.5]岁)均被纳入分析。在前瞻性队列中,739 例美容乳房植入物(1.6%)在中位(IQR)再次手术时间 1.8(0.9-3.1)年后进行了修复,697 例重建乳房植入物(11.8%)在中位(IQR)再次手术时间 1.1(0.5-1.9)年后进行了修复。前瞻性队列中,536 例美容修复(4.2%)和 80 例重建乳房植入物修复(0.7%)是因为 BII,对应于植入物的 0.1%。在回顾性队列中,536 例美容修复(4.2%)和 80 例重建乳房植入物修复(2.7%)是因为 BII。
在这项对患有硅树脂乳房植入物的女性的队列研究中,与局部并发症相比,BII 是乳房植入物修复的一个不太常见的指征,无论是在短期还是长期。与公众对 BII 的日益关注形成对比的是,这些结果表明,局部并发症是乳房植入物修复的一个更为常见的原因。